William H. Towns

1.1k total citations
18 papers, 690 citations indexed

About

William H. Towns is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William H. Towns has authored 18 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William H. Towns's work include Chronic Lymphocytic Leukemia Research (6 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cardiac tumors and thrombi (3 papers). William H. Towns is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cardiac tumors and thrombi (3 papers). William H. Towns collaborates with scholars based in United States, Australia and Italy. William H. Towns's co-authors include Lawrence S. Kirschner, Donna F. Kusewitt, Ludmila Matyakhina, Heiner Westphal, Constantine A. Stratakis, J. Aidan Carney, David Jarjoura, Amy J. Johnson, Virginia M. Goettl and John C. Byrd and has published in prestigious journals such as Circulation, Blood and PLoS ONE.

In The Last Decade

William H. Towns

18 papers receiving 683 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William H. Towns United States	12	325	218	157	146	143	18	690
Timothy McDonnell United States	12	343 1.1×	120 0.6×	406 2.6×	82 0.6×	186 1.3×	19	866
Sandrine Jayne United Kingdom	18	578 1.8×	210 1.0×	142 0.9×	104 0.7×	156 1.1×	37	876
Pu Zhang China	13	450 1.4×	145 0.7×	199 1.3×	99 0.7×	53 0.4×	19	876
Marina Cinelli Italy	16	404 1.2×	123 0.6×	169 1.1×	167 1.1×	394 2.8×	32	884
Emily C. Brantley United States	7	263 0.8×	96 0.4×	268 1.7×	182 1.2×	88 0.6×	8	593
Qunling Zhang China	15	482 1.5×	48 0.2×	390 2.5×	98 0.7×	164 1.1×	51	972
Edward Laane Estonia	14	378 1.2×	116 0.5×	133 0.8×	97 0.7×	112 0.8×	27	754
Weiming Yue China	17	394 1.2×	162 0.7×	192 1.2×	46 0.3×	56 0.4×	49	812
Johannes Fischer Germany	11	248 0.8×	172 0.8×	143 0.9×	53 0.4×	19 0.1×	17	609
Reginald Brys Belgium	13	343 1.1×	101 0.5×	205 1.3×	176 1.2×	51 0.4×	31	841

Countries citing papers authored by William H. Towns

Since Specialization

Citations

This map shows the geographic impact of William H. Towns's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William H. Towns with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William H. Towns more than expected).

Fields of papers citing papers by William H. Towns

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William H. Towns. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William H. Towns. The network helps show where William H. Towns may publish in the future.

Co-authorship network of co-authors of William H. Towns

This figure shows the co-authorship network connecting the top 25 collaborators of William H. Towns. A scholar is included among the top collaborators of William H. Towns based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William H. Towns. William H. Towns is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Patton, John T., Mark Lustberg, Gerard Lozanski, et al.. (2014). The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease. Oncotarget. 6(5). 2693–2708. 21 indexed citations

Liu, Ta-Ming, Yonghua Ling, Mitch A. Phelps, et al.. (2013). OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. Blood. 122(21). 2523–2523. 2 indexed citations

Hertlein, Erin, Kyle A. Beckwith, Gerard Lozanski, et al.. (2013). Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. PLoS ONE. 8(10). e76607–e76607. 46 indexed citations

Woyach, Jennifer A., Engin Bojnik, Amy S. Ruppert, et al.. (2013). Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 123(8). 1207–1213. 156 indexed citations

Mao, Yicheng, Georgia Triantafillou, Erin Hertlein, et al.. (2012). Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies. Clinical Cancer Research. 19(2). 347–356. 26 indexed citations

Rozewski, Darlene M., Sarah E.M. Herman, William H. Towns, et al.. (2012). Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice. The AAPS Journal. 14(4). 872–882. 29 indexed citations

Woyach, Jennifer A., Matthew Stefanovski, Virginia M. Goettl, et al.. (2012). Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease. Blood. 120(21). 183–183. 3 indexed citations

Alinari, Lapo, Courtney Prince, Ryan B. Edwards, et al.. (2012). Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol. Clinical Cancer Research. 18(17). 4600–4611. 33 indexed citations

Alinari, Lapo, Emilia Mahoney, John T. Patton, et al.. (2011). FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 118(26). 6893–6903. 42 indexed citations

10.

Alinari, Lapo, Ryan B. Edwards, Courtney Prince, et al.. (2011). Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol,. Blood. 118(21). 3498–3498. 1 indexed citations

11.

Alinari, Lapo, Emilia Mahoney, John T. Patton, et al.. (2011). FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death. Blood. 118(21). 600–600. 3 indexed citations

12.

Hertlein, Erin, Amy J. Wagner, Jeffrey A. Jones, et al.. (2010). 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 116(1). 45–53. 83 indexed citations

13.

Tep, Chhavy, William H. Towns, Georgeta Mihai, et al.. (2008). Tissue-Specific Ablation of Prkar1a Causes Schwannomas by Suppressing Neurofibromatosis Protein Production. Neoplasia. 10(11). 1213–IN9. 26 indexed citations

14.

Yin, Zhirong, William H. Towns, Xiaoli Zhang, et al.. (2008). Heart-Specific Ablation of Prkar1a Causes Failure of Heart Development and Myxomagenesis. Circulation. 117(11). 1414–1422. 44 indexed citations

15.

Tep, Chhavy, William H. Towns, Georgeta Mihai, et al.. (2008). Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. European Journal of Cancer Supplements. 6(9). 12–12. 1 indexed citations

16.

Towns, William H., et al.. (2007). Mutation of Prkar1a Causes Osteoblast Neoplasia Driven by Dysregulation of Protein Kinase A. Molecular Endocrinology. 22(2). 430–440. 29 indexed citations

17.

Kirschner, Lawrence S., Donna F. Kusewitt, Ludmila Matyakhina, et al.. (2005). A Mouse Model for the Carney Complex Tumor Syndrome Develops Neoplasia in Cyclic AMP–Responsive Tissues. Cancer Research. 65(11). 4506–4514. 142 indexed citations

18.

Towns, William H. & David A. Wink. (2002). Two Views on Clinical Rotations. Nurse Educator. 27(2). 65–67. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact